Differential Opioid Agonist Regulation of the Mouse μ Opioid Receptor*

μ opioid receptors mediate the analgesia induced by morphine. Prolonged use of morphine causes tolerance development and dependence. To investigate the molecular basis of tolerance and dependence, the cloned mouse μ opioid receptor with an amino-terminal epitope tag was stably expressed in human embryonic kidney (HEK) 293 cells, and the effects of prolonged opioid agonist treatment on receptor regulation were examined. In HEK 293 cells the expressed μ receptor showed high affinity, specific, saturable binding of radioligands and a pertussis toxin-sensitive inhibition of adenylyl cyclase. Pretreatment (1 h, 3 h, or overnight) of cells with 1 μM morphine or [D-Ala2MePhe4,Gly(ol)5]enkephalin (DAMGO) resulted in no apparent receptor desensitization, as assessed by opioid inhibition of forskolin-stimulated cAMP levels. In contrast, the morphine and DAMGO pretreatments (3 h) resulted in a 3-4-fold compensatory increase in forskolin-stimulated cAMP accumulation. The opioid agonists methadone and buprenorphine are used in the treatment of addiction because of a markedly lower abuse potential. Pretreatment of μ receptor-expressing HEK 293 cells with methadone or buprenorphine abolished the ability of opioids to inhibit adenylyl cyclase. No compensatory increase in forskolin-stimulated cAMP accumulation was found with methadone or buprenorphine; these opioids blocked the compensatory effects observed with morphine and DAMGO. Taken together, these results indicate that methadone and buprenorphine interact differently with the mouse μ receptor than either morphine or DAMGO. The ability of methadone and buprenorphine to desensitize the μ receptor and block the compensatory rise in forskolin-stimulated cAMP accumulation may be an underlying mechanism by which these agents are effective in the treatment of morphine addiction.

[1]  D. Jasinski,et al.  Etorphine in man. I. Subjective effects and suppression of morphine abstinence , 1975, Clinical pharmacology and therapeutics.

[2]  J. M. Thomas,et al.  Isoform-specific sensitization of adenylyl cyclase activity by prior activation of inhibitory receptors: role of beta gamma subunits in transducing enhanced activity of the type VI isoform. , 1996, Molecular pharmacology.

[3]  H. Okayama,et al.  High-efficiency transformation of mammalian cells by plasmid DNA. , 1987, Molecular and cellular biology.

[4]  A Cowan,et al.  Buprenorphine: combatting drug abuse with a unique opioid , 1995 .

[5]  R. Howells,et al.  Studies on mu and delta opioid receptor selectivity utilizing chimeric and site-mutagenized receptors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  H. Loh,et al.  Molecular characterization of opioid receptors. , 1990, Annual review of pharmacology and toxicology.

[7]  L. S. Bye,et al.  Characterization of the cloned human mu opioid receptor. , 1995, The Journal of pharmacology and experimental therapeutics.

[8]  G. Bell,et al.  Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. , 1994, Molecular pharmacology.

[9]  T. Reisine,et al.  Mutagenesis reveals that agonists and peptide antagonists bind in fundamentally distinct manners to the rat mu receptor than do nonpeptide antagonists , 1994, Regulatory Peptides.

[10]  M. Nirenberg,et al.  Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S. Kato,et al.  Location of Regions of the Opioid Receptor Involved in Selective Agonist Binding (*) , 1995, The Journal of Biological Chemistry.

[12]  A. Cowan,et al.  Buprenorphine and morphine cause antinociception by different transduction mechanisms. , 1991, European journal of pharmacology.

[13]  G. Uhl,et al.  Ligand selectivity of cloned human and rat opioid mu receptors , 1995, Synapse.

[14]  Y. Wong,et al.  Regulation of Multiple Effectors by the Cloned δ‐Opioid Receptor: Stimulation of Phospholipase C and Type II Adenylyl Cyclase , 1995, Journal of neurochemistry.

[15]  Z. Vogel,et al.  Adenylylcyclase Supersensitization in μ-Opioid Receptor-transfected Chinese Hamster Ovary Cells Following Chronic Opioid Treatment (*) , 1995, The Journal of Biological Chemistry.

[16]  H. Loh,et al.  Neuroblastoma Neuro2A cells stably expressing a cloned mu-opioid receptor: a specific cellular model to study acute and chronic effects of morphine. , 1995, Brain research. Molecular brain research.

[17]  H. Kosterlitz,et al.  Agonist and antagonist actions of narcotic analgesic drugs : proceedings of the symposium of the British Pharmacological Society, Aberdeen, July 1971 , 1972 .

[18]  A. Boura,et al.  Actions of etorphine hydrochloride, (M99): a potent morphine-like agent. , 1967, British journal of pharmacology and chemotherapy.

[19]  W. Sadee,et al.  Phosphorylation and Agonist‐Specific Intracellular Trafficking of an Epitope‐Tagged μ‐Opioid Receptor Expressed in HEK 293 Cells , 1995, Journal of neurochemistry.

[20]  G. Bell,et al.  Molecular biology of opioid receptors , 1993, Trends in Neurosciences.

[21]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[22]  B. Cox,et al.  Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at mu opioid receptors. , 1988, Molecular pharmacology.

[23]  J. Thompson,et al.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. , 1976, The Journal of pharmacology and experimental therapeutics.

[24]  Etorphine binds to multiple opiate receptors of the caudate nucleus with equal affinity but with different kinetics. , 1982, Molecular pharmacology.

[25]  G. Uhl,et al.  -mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. , 1994, The Journal of biological chemistry.